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Oxytocin (OT) and arginine vasopressin (AVP) exert 
robust influence on social affiliation and specific cognitive 
processes in healthy individuals. Abnormalities in these 
neuroendocrine systems have been observed in psychotic 
disorders, but their relation to impairments in behavioral 
domains that these endocrines modulate is not well under-
stood. We compared abnormalities of OT and AVP serum 
concentrations in probands with schizophrenia (n = 57), 
schizoaffective disorder (n = 34), and psychotic bipolar dis-
order (n = 75); their first-degree relatives without a history 
of psychosis (n = 61, 43, 91, respectively); and healthy con-
trols (n = 66) and examined their association with emotion 
processing and cognition. AVP levels were lower in schizo-
phrenia (P = .002) and bipolar probands (P = .03) and in 
relatives of schizophrenia probands (P = .002) compared 
with controls. OT levels did not differ between groups. 
Familiality estimates were robust for OT (h2 = 0.79, P = 
3.97e−15) and AVP (h2 = 0.78, P = 3.93e−11). Higher lev-
els of OT were associated with better emotion recognition 
(β = 0.40, P < .001) and general neuropsychological func-
tion (β = 0.26, P = .04) in healthy controls as expected 
but not in any proband or relative group. In schizophrenia, 
higher OT levels were related to greater positive symptom 
severity. The dissociation of OT levels and behavioral func-
tion in all proband and relative groups suggests that risk 
and illness factors associated with psychotic disorders are 
not related to reduced OT levels but to a disruption in the 
ability of physiological levels of OT to modulate social 
cognition and neuropsychological function. Decreased 
AVP levels may be a marker of biological vulnerability in 
schizophrenia because alterations were seen in probands 
and relatives, and familiality was high.
Key words: oxytocin/vasopressin/schizophrenia/bipolar 
disorder/emotion recognition
Introduction
Two phylogenetically ancient neuropeptides, oxytocin 
(OT) and arginine vasopressin (AVP), regulate specific 
social and cognitive processes that are abnormal in schizo-
phrenia. Although OT is commonly known for its role 
in birth and lactation and AVP as an antidiuretic, both 
have widespread influences on emotion and cognition in 
healthy individuals.1–5 Reciprocal interactions between 
OT and AVP facilitate shifts between positive socially 
oriented and defensive states. OT attenuates the stress 
response, improves emotion processing, and can have 
negative effects on verbal learning and memory in healthy 
individuals.1–3,6–8 In contrast, AVP amplifies reactivity to 
stressors and under some conditions can have beneficial 
effects on attention, verbal learning, and memory.1–3,6–8
Several lines of evidence suggest that alterations in 
these endocrine systems may be involved in the patho-
physiology of schizophrenia.9,10 First, some studies have 
reported differences in cerebrospinal fluid and periph-
eral levels of OT and AVP in schizophrenia.11–17 Similar 
results have been reported recently in bipolar disorder.18 
Second, there is notable overlap between the neurobe-
havioral functions modulated by OT and AVP in healthy 
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adults with those that are abnormal in schizophrenia, 
such as social cognition and memory.19–22 For example, 
AVP 1b knockout mice exhibit impairments in memory 
and social behavior.23 Third, these hormones both reg-
ulate physiological activity in brain regions that have 
established functional and structural alterations in the 
disorder.24–28 OT receptor concentrations are highest 
within the hippocampus, septum, and amygdala29 and 
the highest level of brain AVP 1b receptor expression is 
in the hippocampus,30 which is an important brain struc-
ture for memory31 and is abnormal in schizophrenia.25,32 
In preclinical models, haploinsufficient reeler mice, an 
animal model of neural deficits in schizophrenia, show 
reductions in OT receptors especially in the hippocam-
pus and piriform cortex.33 AVP-deficient Brattleboro rats 
also show several phenotypes of schizophrenia including 
sensorimotor gaiting and social cognitive deficits, some 
of which are reversed by antipsychotic drugs.34–36 Fourth, 
postmortem AVP concentrations are reduced in the tem-
poral cortex of schizophrenia patients.37
Although OT and AVP have been implicated in schizo-
phrenia,14,38 the degree to which alterations in these hor-
mone systems contribute to neurobehavioral deficits in 
schizophrenia and other psychotic disorders has not been 
systematically examined. Although supraphysiologic 
doses of OT modulate emotional and cognitive pro-
cesses in healthy individuals20,21 and in some small-sam-
ple schizophrenia studies,39–46 it remains unclear whether 
there are altered physiological protein levels across these 
disorders and whether physiological levels of OT and 
AVP modulate neurobehavioral processes in schizophre-
nia and other psychotic disorders as in healthy individu-
als. Studies of endocrine levels and their neurobehavioral 
associations are needed to address these questions.
Different assay methods may contribute to the con-
siderable variability in findings across previous studies. 
Enzyme immunoassay (EIA) without extraction provides 
greater sensitivity and specificity for OT and AVP47 than 
commercially available radioimmunoassay. With regard to 
endocrine—neurobehavioral associations, 2 small-sample 
studies reported positive associations between peripheral 
OT levels and emotion processing in schizophrenia11,48 and 
trust-related interpersonal interactions have been reported 
to modulate peripheral OT levels in healthy individuals49,50 
but not in schizophrenia.50 In schizophrenia, disruptions 
in peripheral levels of AVP have been linked to poorer 
cognitive functioning and increased positive symptom 
severity.14 In addition to questions about abnormalities in 
peripheral hormone levels and their clinical associations, 
other questions of interest include whether alterations in 
endocrine levels and their associations are present across 
psychotic disorders and whether they are familial.
This study was designed to examine alterations in OT 
and AVP levels and the relation of endocrine levels to 
behavior and cognition in patients with schizophrenia, 
schizoaffective disorder, and psychotic bipolar disorder 
and in their first-degree family members. Our first study 
aim was to compare peripheral OT and AVP levels across 
the patient groups and their relatives. We hypothesized that 
patients and their relatives would show atypical OT and 
AVP levels, compared with controls. Our second aim was 
to evaluate whether peripheral OT and AVP levels were 
associated with clinical symptoms, emotion processing, 
and cognitive functioning. We predicted that higher physi-
ologic levels of OT, which we found previously,51 would be 
associated with less severe symptoms and better emotion 
processing and cognitive functioning, whereas higher AVP 
levels would be associated with more severe symptoms and 
poorer emotion processing and cognitive functioning.
Methods
Participants
This study included participants from the Chicago 
site of the Bipolar and Schizophrenia Network on 
Intermediate Phenotypes (BSNIP) consortium.52 Written 
informed consent was provided by all participants (par-
ticipant assent and parental consent for those <18 years). 
Participants included probands with schizophrenia (n = 
57), schizoaffective disorder (n = 34, 76% bipolar type), 
psychotic bipolar disorder (n = 75), their first-degree 
relatives without a history of psychosis (n = 61, 43, and 
91, respectively), and healthy controls (n = 66; tables 1 
and 2). DSM-IV diagnoses were made at consensus 
meetings using all available information including find-
ings from the Structured Clinical Interview for DSM-IV 
Axis I  Disorders.54 First-degree relatives were adminis-
tered the Structured Interview for DSM-IV Personality 
(SIDP-IV).55 Healthy comparison subjects had no history 
of a psychotic disorder or recurrent depression and no 
known immediate family history of these disorders.
Exclusion criteria included history of head injury with 
loss of consciousness >10 minutes; pregnancy; positive urine 
toxicology screen for common drugs of abuse on the day 
of testing; diagnosis of substance abuse in the past 30 days 
or substance dependence in the past 6 months; history of 
systemic medical or neurological disorder affecting mood or 
cognition; or age-corrected Wide-Range Achievement test 
reading test standard score ≤ 65. A full description of sub-
ject recruitment and clinical assessment is available.52
Measures
Clinical Symptoms and Global Functional Status. Clinical 
symptom assessments included the Positive and Negative 
Syndrome scale,56 Montgomery Asberg Depression 
Rating scale,57 and Young Mania Rating scale.58 
Community functioning was assessed with the Birchwood 
Social Functioning scale.59
Emotion Processing and Cognition. The Penn Emotion 
Recognition-40 test (PENN ER-40)60–62 assesses the abil-
ity to accurately recognize specific emotions conveyed 
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in pictures of faces. Stimuli are 40 faces (half  female) 
expressing 1 of 4 emotions (happiness, sadness, anger, 
fear) or a neutral expression (8 faces per expression). The 
primary outcome measure was the accuracy of affect 
identification. The Brief  Assessment of Cognition in 
Schizophrenia (BACS) battery assessed global neuropsy-
chological function via a composite score.63,64
Serum Hormone Assays. Blood samples were drawn 
in the morning when possible (89% blood draws before 
noon). The percentage of participants drawn before noon 
did not differ across groups (P = .21). Samples were stored 
in plain tubes, spun at 4°C, divided into 300 ul aliquots, 
and stored at −80°C. Samples were batched, diluted in an 
assay buffer to give reliable results within the linear por-
tion of the standard curve (OT 1:4; AVP 1:2), and com-
pleted in duplicate using unextracted plasma. OT and 
AVP were quantified with an EIA kit (Enzo Life Sciences/
Assay Designs).47 These EIAs are highly sensitive (mini-
mal detection levels < 12 pg/ml OT; 4 pg/ml AVP) and spe-
cific with cross-reactivity between OT and AVP < 0.04%. 
Samples were assayed blind to subject information. All 
samples from a given subject were run at the same time. 
OT values > 2000 pg/ml and AVP values > 400 pg/ml were 
re-run to confirm sample accuracy. OT samples consis-
tently remaining higher (10 samples) were set at 2000 pg/
ml, and AVP samples constantly remaining higher (6 sam-
ples) were set at 400 pg/ml for statistical analyses. Intra-
assay coefficients of variation were <10% for both assays.
Statistical Analyses
Hierarchical linear modeling (HLM) with SAS (version 
9.2, SAS Institute Inc, Cary, NC) was used to examine 
group differences in peripheral hormone levels, with fam-
ily membership treated as a random effect because par-
ticipants were nested within families. To test hypotheses 
most firmly supported by prior studies, planned compari-
sons were performed to test for group differences starting 
with schizophrenia patients, their relatives, and healthy 
controls. To determine if  pedigrees with psychotic bipolar 
disorder and schizoaffective disorder probands showed 
similar patterns to schizophrenia families, planned com-
parisons were performed to test for differences between 
these groups. We evaluated whether hormonal effects var-
ied depending on whether patients were taking first- or 
second-generation antipsychotic medications or anticon-
vulsant/mood stabilizers; associations were minimal (sup-
plementary table 1). Next, multivariable linear regression 
modeling was used to examine the degree to which endo-
crine levels were associated with emotion processing, cog-
nition, clinical symptoms, and global functional status. 
When investigating hormone-behavior associations, OT 
and AVP were examined in the same multivariable models, 
so we could measure the contribution of OT controlling 
for AVP and vice versa because OT and AVP levels were 
modestly correlated across groups (r’s ranged between .25 
and .43; supplementary table  2). Because these explor-
atory correlational analyses were performed for heuristic 
purposes to examine the potential clinical significance of 
group differences and clinical associations, we did not cor-
rect for multiple comparisons. All analyses were adjusted 
for age, race, and sex. Significance was set at P < .05; 
trends at P ≥ .05 and P < .10 are reported.
Estimates of familiality (h2) represent the portion of the 
phenotypic variance accounted for by family membership 
and were obtained using sequential oligogenic linkage 
analysis routine.65 To test for the significance of familial-
ity, a maximum likelihood ratio test compared a model in 
which phenotypic variation was explained by family mem-
bership to one not considering variation explained by 
familial factors. Because families were recruited through 
the identification of a psychotic proband and not as a rep-
resentative community sample, a correction was applied 
to account for this ascertainment bias.66
Results
Baseline Differences in Cognition, Social Functioning, 
and Emotion Recognition
Consistent with multisite BSNIP consortium findings,52,53 
there were significant group differences on the BACS com-
posite and in community functioning (P’s < .001; Tables 1 
and 2). All proband groups performed worse than healthy 
controls on both measures (P’s < .001). Schizophrenia 
probands also performed worse than bipolar probands on 
both measures (P’s < .05). On the PENN ER-40, schizo-
phrenia probands (P < .001) performed worse than healthy 
controls and bipolar probands (P = .04). Differences 
between relatives and healthy controls were not significant.
Group Differences and Familiality Estimates for 
Peripheral Concentrations of OT and AVP
HLM analyses yielded significant group differences in AVP 
for schizophrenia probands and their relatives compared 
to controls, but not OT levels (figure 1). Schizophrenia pro-
bands (B = −0.44, SE = 0.14, P = .002) and their relatives 
(B = −0.37, SE = 0.12, P = .002) showed lower AVP but not 
OT levels, compared with controls. Bipolar probands (B = 
−0.27, SE = 0.13, P = .03) also had lower levels of AVP 
but not OT, compared with controls. Relatives of bipolar 
probands showed a trend for lower levels of AVP but not 
OT, compared with controls (B = −0.20, SE = 0.11, P = 
.07). Among the smaller sample of schizoaffective families, 
probands (M = 4.24, SE = 0.14) showed a trend toward 
lower levels of AVP, compared with controls (M = 4.51, 
SE = 0.09; B = −0.26, SE = 0.16, P = .09), similar in mag-
nitude to the reduction seen in bipolar probands. Post hoc 
comparisons yielded no significant differences in peptides 
between proband groups or first-degree relative groups. All 
proband and relative groups showed a higher proportion 
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of individuals with lower levels of AVP (ie, <1 SD from 
controls), compared with controls using the Lambda67,68 
statistic (supplementary table 3). Additionally, there were 
more schizophrenia probands than bipolar probands with 
low levels of AVP (P = .04). The same pattern was demon-
strated when comparing relatives of schizophrenia to rela-
tives of bipolar probands (P = .05).
Familiality estimates were highly significant for both 
OT (h2 = 0.79, SE = 0.08, P = 3.97e−15) and AVP (h2 
= 0.78, SE = 0.10, P = 3.93e−12) in the pooled data of 
proband families. Correlations between relative and pro-
band’s OT and AVP levels were also robust (figure  2). 
Comparable familiality estimates were observed in 
schizophrenia and bipolar pedigrees (supplementary 
table  4). In probands, chlorpromazine equivalents of 
antipsychotic treatment69 were not associated with hor-
mone levels. Excluding first-degree relatives taking psy-
chiatric medications from the HLM analysis did not 
change the pattern of  results.
Hormone-Behavior Associations
Emotion Processing. Higher levels of  OT were associ-
ated with better emotion recognition accuracy in healthy 
Table 1. Demographics and Clinical Characteristics for Health Comparison Subjects and Probands with Schizophrenia, Schizoaffective 









Post HoceM (SD) M (SD) M (SD) M (SD)
Age (y) 35.31 (12.92) 37.50 (14.12) 32.97 (13.61) 37.18 (12.65) —
Education (y) 12.86 (2.49) 13.67 (2.89) 14.11 (2.58) 15.36 (2.44) d > a, b, c; c > a
WRAT 94.24 (15.67) 100.00 (16.63) 103.93 (15.09) 103.33 (12.37) b, c, d > a
BACS composite −1.39 (1.42) −1.11 (1.20) −0.77 (1.31) 0.14 (1.14) d > a, b, c; c > a
PENN ER-40 
(% correct)
76.75 (11.43) 79.77 (9.85) 80.25 (8.46) 82.64 (7.37) d, c > a
SFS 126.07 (19.74) 125.53 (19.81) 140.05 (20.21) 162.57 (14.65) d > a, b, c; c > a, b
PANSS
 Positive subscale 19.41 (5.66) 19.59 (4.71) 12.84 (3.89) — a, b > c
 Negative subscale 20.21 (7.02) 17.38 (6.60) 13.68 (4.53) — a, b > c
YMRS 7.86 (6.48) 8.26 (5.57) 5.62 (6.21) — a, b > c
MADRS 9.80 (7.26) 15.32 (9.85) 10.83 (9.31) — b > a, c
n (%) n (%) n (%) n (%)
Male 35 (61) 15 (44) 24 (32) 28 (42) a > b, c, d
Race
 Caucasian 25 (44) 18 (53) 58 (77) 37 (56) c > a, b, d
 African American 24 (42) 15 (44) 11 (15) 18 (27) a, b > c, d
 Other 8 (14) 1 (3) 6 (8) 11 (17) d > b
Blood draw ≤ noon 49 (86) 32 (94) 67 (89) 63 (95) —
Medication classf
 Antipsychotic
  First generation 12 (21) 5 (15) 3 (4) — a, b > c
   Second 
generation
43 (75) 25 (73) 51 (68) — —
  Anticonvulsant/ 
mood stabilizer
10 (17) 22 (65) 53 (71) — b, c > a
  Lithium — 2 (6) 22 (29) — c > a, b
  Valproic acid 6 (10) 7 (20) 13 (17) — —
 Antidepressant 20 (35) 21 (62) 35 (47) — b, c > a
 Sedative/anxiolytic 15 (26) 13 (38) 22 (29) — —
 Stimulant 5 (9) 2 (6) 11 (15) — —
 Anticholinergic 5 (9) 1 (3) 4 (5) — —
Note: WRAT, Wide-Range Achievement Test-IV: reading test; BACS, Brief  Assessment of Cognition in Schizophrenia race-
adjusted composite (higher = better functioning); PENN-ER-40, Penn Emotion Recognition-40 test; SFS, Social Functioning 
scale (higher = better functioning); PANSS, Positive and Negative Syndrome scale; YMRS, Young Mania Rating scale; MADRS, 
Montgomery Asberg Depression Rating scale.
a, b, c and d—all differences noted are at P < .05.
ePost hoc tests were computed when the omnibus F test was significant at P < .05.
fConsistent with Tamminga et al.52 and Hill et al.53
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controls (β = 0.40, B = 3.76, SE = 1.13, P < .001) but 
not in patients with schizophrenia or their relatives 
(Figure  3). Higher levels of  OT in healthy individuals 
were associated with better emotion recognition of  neu-
tral (β = 0.35, B = 7.17, SE = 2.64, P < .01), happy, (β 
= 0.27, B = 1.44, SE = 0.69, P = .04), and sad faces (β = 
0.26, B = 6.03, SE = 2.96, P = .04). OT levels also were 
not associated with emotion recognition in bipolar or 
schizoaffective probands or their relatives (figure 3). All 
associations were significantly reduced relative to con-
trols (Fisher’s r to z transformations, P’s < .05) except 
for the smaller schizoaffective relative group for whom 
the difference was at the trend level (P = .10). AVP levels 
were not significantly associated with emotion recogni-
tion in any group.
Cognition. Similar to the emotion recognition results, 
higher levels of  OT were associated with better global 
neuropsychological performance in healthy controls (β 
= 0.26, B = 0.36, SE = 0.17, P = .04) but not in any 
proband or relative group. AVP levels were not associ-
ated with overall neuropsychological performance in 
any group.
Clinical Symptoms. In schizophrenia, higher levels 
of  OT, but not AVP, were associated with more severe 
positive symptoms (β = 0.32, B = 2.67, SE = 1.17, P 
= .02). Because the sample was clinically stable for at 
least 1 month at the time of  the study, this may reflect 
a relation between higher OT levels and the presence 
of  more significant residual or treatment nonresponsive 
symptoms. There was a trend for higher levels of  OT 
to be associated with more severe negative (β = 0.31, 
B = 2.36, SE = 1.33, P = .08) and manic symptoms (β 
= 0.32, B = 2.03, SE = 1.06, P = .06) in schizoaffec-
tive probands. In schizoaffective probands, those with 
Table 2. Demographics, History of Psychosis, and Personality Traits for Healthy Comparison Subjects, First-Degree Relatives of 











Post HoceM (SD) M (SD) M (SD) M (SD)
Age (y) 42.77 (15.83) 39.79 (16.39) 41.01 (15.47) 37.18 (12.65) —
Education (y) 13.97 (2.38) 14.40 (2.86) 15.19 (2.64) 15.36 (2.44) c, d > a, b
WRAT 98.82 (14.67) 105.29 (15.37) 104.15 (13.88) 103.33 (12.37) —
BACS composite −0.11 (1.03) 0.26 (1.02) 0.17 (1.12) 0.14 (1.14) —
PENN ER-40 
(% correct)
81.08 (6.22) 81.18 (7.05) 82.27 (7.52) 82.64 (7.37) —
SFS 150.84 (18.33) 148.11 (20.55) 152.46 (18.41) 162.57 (14.65) d > a, b, c
n (%) n (%) n (%) n (%)
Male 15 (24) 14 (33) 32 (35) 28 (42) —
Race
 Caucasian 33 (54) 27 (63) 78 (86) 37 (56) c>a, b, d
 African American 22 (36) 13 (30) 10 (11) 18 (27) a, b, d > c
 Other 6 (10) 3 (7) 3 (3) 11 (17) d > b
Blood draw ≤ noon 53 (87) 42 (98) 79 (87) 63 (95) —
Medications
 No medications 53 (87) 33 (77) 62 (68) — —
 Antipsychotic
   Second 
generation
2 (3) 2 (4) 4(4) — —
  Anticonvulsant/ 
mood stabilizer
— 4 (9) 7 (7) — —
  Lithium — 1 (2) 1 (1) — —
  Valproic acid 1 (2) 2 (5) 1 (1) — —
 Antidepressant 7 (11) 7 (16) 21 (23) — —
 Sedative/anxiolytic 3 (5) 2 (5) 8 (9) — —
 Stimulant — 3 (7) 4 (4) — —
Note: WRAT, Wide-Range Achievement Test-IV: reading test; PENN-ER-40, Penn Emotion Recognition-40 test; SFS, Social 
Functioning scale (higher = better functioning); BACS, Brief  Assessment of Cognition in Schizophrenia race-adjusted composite score 
(higher = better functioning); medication class consistent with Tamminga et al52 and Hill et al.53
a, b, c and d—all differences noted are at P < .05.
ePost hoc tests were computed when the omnibus F test was significant at P < .05.
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lower AVP levels had more severe manic (β = −0.50, B 
= −4.06, SE = 1.29, P = .002) and positive symptoms (β 
= −0.40, B = −2.68, SE = 1.12, P = .02). Levels of  OT 
and AVP were not related to symptom severity in bipo-
lar probands. Across all relatives, regardless of  proband 
diagnosis, those with a Cluster A (psychosis spectrum) 
personality disorder had lower levels of  AVP than those 
without a Cluster A diagnosis (β = −0.17, B = 0.55, SE 
= 0.23, P = .02).
Community Functioning and Sex Differences. OT and 
AVP were not associated with community functioning 
in any group. There were no significant sex by group 
interactions in hormone levels, and there were no sex dif-
ferences in any hormone-behavior relationships.
Discussion
The results of this study demonstrate abnormalities of 
serum AVP and in the modulatory function of OT on 
emotion processing and cognitive functioning among 
individuals with psychotic disorders and their first-
degree relatives. Both schizophrenia patients and their 
relatives showed decreased levels of AVP compared with 
the healthy comparison group; similar findings were 
seen in bipolar patients and their relatives albeit to a less 
Fig. 1. Comparison of serum vasopressin (a) and oxytocin levels (b) between the healthy comparison group, psychotic probands, and 




prominent degree, and AVP levels were highly familial. 
Additionally, relatives with a psychosis spectrum per-
sonality disorder showed lower AVP levels than other 
relatives. Thus, reduced AVP levels have several charac-
teristics of a promising endophenotype across psychotic 
disorders.
Findings with OT were notably different. OT levels 
were not reduced in any proband or relative group even 
though familiality was highly significant across psychotic 
disorders. Rather, findings with OT were most notable 
in their association with clinical symptoms and reduced 
association with neurobehavioral functions. First, OT 
levels in schizophrenia and schizoaffective probands were 
associated with higher rather than lower clinical symp-
tom levels. Second, the positive association between OT 
levels and better social cognition and general neuropsy-
chological function observed in our healthy controls and 
widely reported in the literature3,4 was not seen in any 
proband or relative group. This finding suggests a dis-
sociation between OT levels and behavioral function in 
both probands with psychotic disorders and their unaf-
fected relatives, such that hormone levels appear to have 
a reduced capacity to modulate affective and neuropsy-
chological functioning. This pattern suggests alterations 
in downstream processes at the level of OT receptors, 
signal transduction, or in the neurophysiological integ-
rity of brain regions dense with OT receptors that may be 
impacted by illness and risk rather than an abnormality 
in OT peptide levels.
Our findings are consistent with previous studies dem-
onstrating AVP dysregulation in schizophrenia.14,15,17,38,70 
Of note, however, the direction of effects in prior work 
has been mixed, perhaps in relation to state of illness 
and assays used. For example, in contrast to our clini-
cally stable patients with schizophrenia showing lower 
levels of AVP, studies of unmedicated acutely ill first-epi-
sode patients show higher levels of AVP, compared with 
healthy controls in 2 of 3 studies.14,15,17 Higher AVP levels 
in acutely ill patients maybe the result of a dysregulated 
biological stress response system.71
The present findings extend prior work by demonstrat-
ing a similar pattern of abnormality in psychotic bipo-
lar disorder and schizoaffective probands. There was a 
similar trend in the relatives of bipolar probands, and 
all relative groups had a higher percent of individuals 
with AVP levels 1 SD below healthy controls. Also, we 
observed that findings in family members were greater in 
those with psychosis spectrum personality traits. These 
findings suggest that alterations in AVP occur across psy-
chotic disorders rather than selectively in schizophrenia. 
Medications could be confounding factors in our proband 
data because they varied based on clinical indication. 
However, statistical associations of effects with medica-
tion treatments were not significant, and AVP alterations 
in untreated relatives were similar to those seen in the 
patient probands. This pattern of effects is more consis-
tent with disease-related rather than treatment-induced 
abnormalities.
In contrast to effects seen in serum AVP, we did not 
find significant alterations in OT levels in probands with 
psychotic disorders or their first-degree relatives. This 
is consistent with our previous studies of schizophrenia 
Fig. 2. Relationship between oxytocin and vasopressin levels in relatives and probands. Values for each relative are plotted relative to 
their family member proband. Data represents 203 pedigrees and 144 probands. Maximum levels for oxytocin and vasopressin were used 
as described in the text.
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patients.14,51 The only other study to date using the same 
assay methodologies showed lower levels of peripheral OT 
in schizophrenia patients with polydipsia hyponatremia.11
In contrast to our previous findings,51 OT levels were 
associated with higher clinical symptom levels. At least 3 
factors might have contributed to these differences. First, 
schizophrenia probands in this study were recruited from 
the community rather than a clinic and exhibited higher 
levels of positive symptoms than our previous study of 
chronic patients.51 Second, given our larger sample sizes we 
were able to examine OT-symptom associations separately 
for schizophrenia and schizoaffective probands. Analyses 
in our previous study combined both disorders. Third, OT 
levels were higher in probands in the present study. One 
possibility is that OT may have a protective or beneficial 
effect when the range of OT values is lower, but detrimen-
tal effects when OT values are higher. Alternatively, it is 
possible that higher OT levels in probands may have been 
a compensatory response and thus be mitigating symp-
toms that might otherwise be even higher.
With respect to clinical associations, relationships 
between OT and clinical symptoms were stronger in schizo-
phrenia spectrum disorders than bipolar probands. Thus, 
the clinical significance of OT levels may be greater in 
psychotic disorders with higher levels of persistent positive 
and negative symptoms and poorer community function-
ing. The implications of this study for the use of exogenous 
OT as a treatment are indirect but worthy of note. While 
treatment-induced supraphysiological levels may have 
direct positive effects or reset responsivity of brain systems 
to OT modulation,40,44 the absence of abnormal physiolog-
ical OT levels, the lack of association between OT levels 
and social cognition, and the positive relationship between 
OT levels and symptom severity do not in themselves offer 
support for this therapeutic strategy.
Concentrations of both peripheral hormone levels 
were highly familial, and recent investigations suggest 
that variations in genes for OT (OXTR) and AVP (V1aR) 
show associations with schizophrenia, symptom sever-
ity, and treatment response to clozapine in schizophrenia 
patients.72–75 Hence, the presence of alteration in family 
members and its familiality suggest that OT and AVP 
genes or other factors influencing the impact of these 
hormones on brain and behavioral function may contrib-
ute to psychosis vulnerability.
Limitations of  this study include a cross-sectional 
study design, and a single measurement of  hormone lev-
els. The study was designed to assess trait-like alterations 
Fig. 3. Raw correlations showing (A) Higher serum levels of oxytocin are associated with better performance on a facial emotion 
recognition test in the healthy comparison group but not in (B) schizophrenia probands and their first-degree relatives, (C) schizoaffective 
probands and their first-degree relatives, or (D) psychotic bipolar and their first-degree relatives.
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rather than clinical state relationships, so the range of 
symptom severity was limited by design. Thus, rela-
tions of  hormones to active symptoms may be under-
estimated, or different patterns of  alterations might 
be seen during acute episodes of  illness. Experimental 
approaches, such as administration of  intranasal OT or 
agents that affect the AVP system are needed to assess 
therapeutic implications and complement studies of 
peripheral hormone levels. In addition, it has been sug-
gest that perturbations of  the hypothalamic-pituitary-
adrenal  axis may be a risk factor for the development 
of  psychotic disorders.71 This and other hormones merit 
study in order to examine patterns and specificity of 
hormone alterations associated with psychotic disor-
ders. Finally, although neuropeptides in the peripheral 
circulation do not readily cross the blood-brain barrier, 
most peripheral OT and AVP are synthesized within 
the brain and released into the periphery via the pos-
terior pituitary. Animal data indicate that central and 
peripheral levels of  OT are correlated.76 While central 
nervous system implications of  peripheral measures are 
uncertain, peripheral hormone levels, both at baseline 
and in reaction to social stimuli have been associated in 
numerous studies with multiple behavioral parameters 
that indicate the relevance of  peripheral measures of 
neurobehavioral functions.77,78
Overall, our findings extend previous work in schizo-
phrenia to suggest that OT and AVP may be involved in 
pathophysiology across psychotic disorders and that they 
may be involved in the vulnerability to schizophrenia as 
indicated by findings in first-degree relatives. The reduced 
modulation of relevant neurobehavioral functions by OT 
even in the context of normal peripheral hormone levels 
suggests that a downstream alteration in OT receptors or 
relevant limbic and neocortical systems where the recep-
tors are densely expressed, rather than an alteration in 
hormone levels, may contribute to social cognition defi-
cits in psychotic disorders.
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